Cellectis(NASDAQ) CLLS

Market Cap$107.04M

Since IPO (2015)-96%

5 Year-88%

1 Year-56%

1 Month-56%

Premium Feature

Moneyball Superscore

59/100

$1.48

+0.68%

+0.01Today

Cellectis last closing stock price
Metric	Price	Date
Last close	USD 1.48	2026-09-28

Cellectis stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-1.99%	USD 1.51	2026-09-21
1 month	-56.47%	USD 3.40	2026-08-28
3 month	-50.67%	USD 3.00	2026-06-30
Year to date	-69.42%	USD 4.84	2025-12-31
1 year	-55.95%	USD 3.36	2025-09-26
3 year	-6.33%	USD 1.58	2023-09-29
5 year	-88.28%	USD 12.63	2021-09-29
Since inception	-96.04%	USD 37.35	2015-03-26

Cellectis Financials at a Glance

Market Cap

$107.04M

Revenue (TTM)

$56.59M

Net Income (TTM)

-$65.35M

EPS (TTM)

-$0.65

P/E Ratio

-2.28

Dividend

$0.00

Beta (Volatility)

1.39 (Average)

Dividend

$0.00

Beta (Volatility)

1.39 (Average)

Price

$1.48

Volume

850

Open

$1.47

Price

$1.48

Volume

850

Open

$1.47

Previous Close

$1.48

Daily Range

$1.43 - $1.50

52-Week Range

$1.25 - $5.48

Estimated Earnings Date

Nov 13, 2026

Dividend

$0.00

Beta (Volatility)

1.39 (Average)

Price

$1.48

Volume

850

Open

$1.47

Previous Close

$1.48

Daily Range

$1.43 - $1.50

52-Week Range

$1.25 - $5.48

Estimated Earnings Date

Nov 13, 2026

CLLS News

Page 1

CLLS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cellectis

Cellectis S.A. is a biotechnology firm focused on developing immuno-oncology therapies that utilize gene-edited T-cells. The company aims to create innovative treatments for various cancers by engineering T-cells to specifically target and eliminate malignant cells.

Products and Services

UCART19: Allogeneic T-cell therapy for CD19-expressing blood cancers
ALLO-501 and ALLO-501A: Targeting diffuse large B-cell lymphoma
UCART123 and UCART22: Designed for acute myeloid leukemia and B-cell acute lymphoblastic leukemia

Growth Outlook

Strong pipeline with multiple candidates in clinical development
Strategic partnerships enhancing research capabilities and market reach
Focus on expanding therapeutic applications in oncology

Financial Highlights

Q2 2026 revenue of $5.22 million, showing consistent demand for therapies
Trailing twelve months (TTM) gross profit margin at 74.68%, indicating strong product potential
Cash and short-term investments totaling $166.85 million, providing operational stability

Cellectis S.A. operates in a dynamic sector with a focus on innovative cancer therapies. The company’s robust pipeline and strategic partnerships position it well for future growth. Recent financial data indicates a solid gross profit margin, reflecting the potential for successful product commercialization. With significant cash reserves, Cellectis is equipped to navigate the challenges of clinical development and market entry. The biotechnology industry continues to evolve, and Cellectis is poised to play a significant role in advancing cancer treatment options.

AI Generated • Sep 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

229

CEO

André Choulika, PhD

Website

www.cellectis.com

Headquarters

Paris, IF 75013, FR

CLLS Financials

Key Financial Metrics (TTM)

Gross Margin

74.68%

Operating Margin

-107.92%

Net Income Margin

-115.36%

Return on Equity

-94.14%

Return on Capital

-16.89%

Return on Assets

-24.41%

Earnings Yield

-43.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$107.04M

Shares Outstanding

72.33M

Volume

850

Avg. Volume

73.72K

Financials (TTM)

Gross Profit

$42.27M

Operating Income

-$61.86M

EBITDA

-$55.49M

Operating Cash Flow

-$41.89M

Capital Expenditure

-$2.18M

Free Cash Flow

-$44.06M

Cash & ST Invst.

$166.85M

Total Debt

$84.57M

Cellectis Performance Analysis

Cellectis annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 19,181,501	-36.7%
2023	2023-12-31	USD 756,169	-96.1%
2024	2024-12-31	USD 41,431,683	5379.2%
2025	2025-12-31	USD 73,174,719	76.6%

Cellectis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	110.3%
Q4	2025-12-31	-70.4%
Q1	2026-03-31	-44.2%
Q2	2026-06-30	-9.9%

Cellectis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.33	-8.3%
2023	2023-12-31	USD -1.78	-23.9%
2024	2024-12-31	USD -0.41	-77.2%
2025	2025-12-31	USD -0.68	66.9%

Cellectis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	102.5%
Q4	2025-12-31	-4676.3%
Q1	2026-03-31	33.3%
Q2	2026-06-30	-22.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$5.22M

-68.8%

Gross Profit

$815.87K

-94.3%

Gross Margin

15.62%

N/A

Market Cap

$107.04M

N/A

Market Cap/Employee

$467.43K

N/A

Employees

229

N/A

Net Income

-$21.79M

+8.2%

EBITDA

-$21.04M

-26.3%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$166.85M

-14.9%

Total Debt

$84.57M

-10.8%

Accounts Receivable

$13.64M

-53.5%

Inventory

$0.00

N/A

Long Term Debt

$76.49M

-6.5%

Short Term Debt

$8.09M

-37.5%

Return on Assets

-24.41%

N/A

Return on Invested Capital

-46.11%

N/A

Free Cash Flow

-$14.54M

-36.9%

Operating Cash Flow

-$14.28M

-38.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KRROKorro Bio, Inc.

KRROKorro Bio, Inc.$9.51-0.63%

ALDXAldeyra The

ALDXAldeyra The$1.16-3.73%

MREOMereo BioPharma Group plc

MREOMereo BioPharma Group plc$0.37+0.00%

ACIUAC Immune S.A.

ACIUAC Immune S.A.$2.61+3.57%

AMRNAmarin Corporation plc

AMRNAmarin Corporation plc$13.25+0.38%

DBVTDBV Technologies S.A.

DBVTDBV Technologies S.A.$11.64+0.69%

LRMRLarimar Therapeutics, Inc.

LRMRLarimar Therapeutics, Inc.$3.17+3.09%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$34.43+6.17%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$142.29-6.05%

NOKNokia

NOKNokia$10.12-2.60%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$34.83+3.20%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.04-3.22%

FFord Motor Company

FFord Motor Company$12.38-2.60%

INTCIntel

INTCIntel$116.03-5.67%

Questions About CLLS

What is the current price of Cellectis?

Cellectis is trading at $1.48 per share.

What is the 52-week range for Cellectis?

Over the past 52 weeks, Cellectis has traded between $1.25 and $5.48.

How much debt does Cellectis have?

As of the most recent reporting period, Cellectis reported total debt of $104.28M.

How much cash does Cellectis have on hand?

Cellectis reported $35.75M in cash and cash equivalents in its most recent financial results.

What is Cellectis’s dividend yield?

Cellectis does not currently have a dividend yield.

Cellectis(NASDAQ) CLLS

Cellectis Financials at a Glance

CLLS News

Why Cellectis' Shares Rose 22.7% This Week

Why Cellectis Stock Rose 20.7% This Week

These Gene-Editing Pioneers Are Making Bold Bets in Agriculture

Did Cellectis Just Provide a Glimpse of the Future of Cellular Medicine?

Is Cellectis SA Stock a Buy Now?

Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?

Why Micron Technology, Mechel, and Cellectis Slumped Today

Why Mallinckrodt, Universal Insurance Holdings, and Cellectis Slumped Today

CLLS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cellectis

CLLS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cellectis Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CLLS

What is the current price of Cellectis?

What is the 52-week range for Cellectis?

How much debt does Cellectis have?

How much cash does Cellectis have on hand?

What is Cellectis’s dividend yield?

Premium Investing Services